Issue 5/2022
Content (21 Articles)
EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis
Huimin Yang, Jinxiu Zhu, Rendong Xiao, Yuhang Liu, Fanglin Yu, Lin Cai, Minglian Qiu, Fei He
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma
Jutatip Panaampon, Ryusho Kariya, Seiji Okada
Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long term follow-up: implication in the progression of cancer
Kawaljit Kaur, Meng-Wei Ko, Franklin Chen, Anahid Jewett
Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma
Michael W. Knitz, Laurel B. Darragh, Thomas E. Bickett, Shilpa Bhatia, Sanjana Bukkapatnam, Jacob Gadwa, Miles Piper, Sophia Corbo, Diemmy Nguyen, Benjamin Van Court, Ayman Oweida, Sana D. Karam
Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
Kang Chen, Wei Wei, Lei Liu, Zhu-Jian Deng, Le Li, Xiu-Mei Liang, Ping-Ping Guo, Lu-Nan Qi, Zhi-Ming Zhang, Wen-Feng Gong, Shan Huang, Wei-Ping Yuan, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong
LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2
Lin Zhou, Jian Li, Mingmei Liao, Qi Zhang, Mei Yang
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience
Seoyoung Lee, Hyo Sup Shim, Beung-Chul Ahn, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min Hee Hong
Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma
Markus Bo Schoenberg, Tong Zhu, Jingcheng Hao, Julian Nikolaus Bucher, Xiaokang Li, Xinyu Li, Yongsheng Han, Dionysios Koliogiannis, Michaela Svihla, Markus Otto Guba, Jens Werner, Alexandr V. Bazhin
Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide
Jen-Chih Tseng, Jing-Xing Yang, Yi-Ling Liu, Yu-Wen Su, Alan Yueh-Luen Lee, Ya-Wen Chen, Ko-Jiunn Liu, Yunping Luo, Yi-Ren Hong, Tsung-Hsien Chuang
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study
Mitsuro Fukuhara, Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia
Hana Triki, Ken Declerck, Slim Charfi, Wala Ben Kridis, Kais Chaabane, Sawssan Ben Halima, Tahya Sellami, Ahmed Rebai, Wim Vanden Berghe, Boutheina Cherif
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival
Tyler C. Haddad, Songzhu Zhao, Mingjia Li, Sandip H. Patel, Andrew Johns, Madison Grogan, Gabriella Lopez, Abdul Miah, Lai Wei, Gabriel Tinoco, Brian Riesenberg, Zihai Li, Alexa Meara, Erin M. Bertino, Kari Kendra, Gregory Otterson, Carolyn J. Presley, Dwight H. Owen
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
Li Cheng, Todd Creasy, Fernanda Pilataxi, Lydia Greenlees, Luis Vence, Sriram Sridhar, Katie Streicher
Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma
Bolun Zhou, Shugeng Gao
Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment
Xueying Wang, Kui Cao, Erliang Guo, Xionghui Mao, Changming An, Lunhua Guo, Cong Zhang, Junnan Guo, Xianguang Yang, Ji Sun, Weiwei Yang, Xiaomei Li, Susheng Miao
The Crohn’s-like lymphoid reaction density: a new artificial intelligence quantified prognostic immune index in colon cancer
Minning Zhao, Su Yao, Zhenhui Li, Lin Wu, Zeyan Xu, Xipeng Pan, Huan Lin, Yao Xu, Shangqing Yang, Shenyan Zhang, Yong Li, Ke Zhao, Changhong Liang, Zaiyi Liu
The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor
Ding Nie, Qiuyue Fang, Jianhua Cheng, Bin Li, Mingxuan Li, Hongyun Wang, Chuzhong Li, Songbai Gui, Yazhuo Zhang, Peng Zhao
Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus
Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Li-na He, Haifeng Li, Yuhong Wang, Tao Chen, Shaodong Hong, Li Zhang
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus
Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Li-na He, Haifeng Li, Yuhong Wang, Tao Chen, Shaodong Hong, Li Zhang
MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues
Tony Yao, Patrick T. Rudak, Céline M. Laumont, Alex R. Michaud, Rasheduzzaman Rashu, Natasha N. Knier, Paula J. Foster, Hamish E. G. McWilliam, Jose A. Villadangos, Brad H. Nelson, Gabriel E. DiMattia, Trevor G. Shepherd, S. M. Mansour Haeryfar
A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer
Jianjiao Ni, Yue Zhou, Shengping Wang, Tiantian Guo, Jie Hu, Qian Chu, Xi Yang, Li Chu, Xiao Chu, Yida Li, Zhengfei Zhu